Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face an uncertain future in the incoming Trump administration.

Top Medicare Part D drugs without price negotiations have seen a 98% increase in list prices since their launch. Read more here.

((This Jan. 13 story has been corrected to say 'drugmakers will ask,' not 'Eli Lilly has asked' to pause negotiations, after the company clarified, in the headline & paragraph 1)) (Reuters) - Drugmakers will ask the U.

Eli Lilly & Co. said it and other drugmakers will ask the Trump administration to pause drug-price negotiations, even as Biden-appointed officials prepare a new list of medicines that should be targeted.

Eli Lilly (NYSE:LLY) has reportedly asked the Biden administration to pause negotiations over drug pricing, citing problems with the process. Lilly CEO Dave Ricks said in an interview that the company has requested a pause,